Integra LifeSciences Holdings Corporation $IART Shares Sold by Paradigm Capital Management Inc. NY

Key Points

• Paradigm Capital Management Inc. has decreased its stake in Integra LifeSciences by 3.2%, now holding 1,385,200 shares, making up approximately 1.7% of its portfolio.
• Integra LifeSciences reported earnings of $0.45 per share for the most recent quarter, exceeding analyst expectations of $0.43 and generating revenues of $415.61 million.
• Several analysts have revised their price targets for Integra LifeSciences, with Wells Fargo reducing its target from $25.00 to $13.00, indicating a shift in market sentiment for the stock.

Paradigm Capital Management Inc. NY cut its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 3.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,385,200 shares of the life sciences company's stock after selling 45,900 shares during the quarter. Integra LifeSciences comprises 1.7% of Paradigm Capital Management Inc. NY's investment portfolio, making the stock its 19th biggest holding. Paradigm Capital Management Inc. NY owned approximately 1.78% of Integra LifeSciences worth $30,461,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. CWM LLC increased its stake in shares of Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock valued at $147,000 after purchasing an additional 5,367 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $223,000. NorthRock Partners LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $251,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $251,000. Finally, Natixis Advisors LLC bought a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $297,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

NASDAQ IART traded down $0.03 on Wednesday, reaching $15.13. The company had a trading volume of 1,558,740 shares, compared to its average volume of 1,309,486. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $1.18 billion, a PE ratio of -2.32, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20. The firm's 50 day moving average price is $13.19 and its 200 day moving average price is $15.90. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same quarter in the previous year, the business earned $0.63 EPS. The company's quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on IART shares. JPMorgan Chase & Co. dropped their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. JMP Securities dropped their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Finally, Wells Fargo & Company dropped their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of "Reduce" and an average price target of $18.43.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.